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a b s t r a c t
The vasoactive kinin B1 receptor (B1R) is overexpressed in the retina of diabetic rats in response to
hyperglycemia and oxidative stress. The aim of the present study was to determine whether B1R could
contribute to the early retinal blood flow changes occurring in diabetes. Male Wistar rats were rendered
diabetic with a single i.p. injection of Streptozotocin (STZ) and studied 4 days or 6 weeks after diabetes
induction. The presence of B1R in the retina was confirmed by Western blot. The impact of oral
administration of the B1R selective antagonist SSR240612 (10 mg/kg) was measured on alteration of
retinal perfusion in awake diabetic rats by quantitative autoradiography. Data showed that B1R was
upregulated in the STZ-diabetic retina at 4 days and 6 weeks. Retinal blood flow was not altered in 4-day
diabetic rats compared with age-matched controls but was significantly decreased following SSR240612
treatment. In 6-week diabetic rats, retinal blood flow was markedly reduced compared to control rats
and SSR240612 did not further decrease the blood flow. These results suggest that B1R is upregulated in
STZ-diabetic retina and has a protective compensatory role on retinal microcirculation at 4 days but not
at 6 weeks following diabetes induction.
 2011 Elsevier Ltd. All rights reserved.
1. Introduction
The kallikrein-kinin system is involved in micro- and macro-
vascular complications associated with diabetic nephropathy, cardio-
myopathy and polyneuropathy (Buleon et al., 2008; Couture and
Girolami, 2004; Dias et al., 2010; Gabra et al., 2005; Westermann
et al., 2009). Through the activation of two G-protein coupled recep-
tors, named B1 (B1R) and B2 (B2R) (Regoli and Barabe, 1980; Regoli
et al., 1998), these inflammatory peptides mediate enhanced capil-
lary permeability, edema, leukocytes infiltration, vasodilation and
regulation of local blood flow (Couture et al., 2001; Marceau et al.,
1998). The activation of either receptor induces release of nitric
oxide (NO) and prostaglandins (PGs) from vascular endothelial cells
which consequently promote vasodilation (Ahluwalia and Perretti,
1999; McLean et al., 1999). The widely distributed B2R mediates the
acute effects of bradykinin (BK) and kallidin (KD). In contrast, B1R is
virtually absent in physiological conditions and is highly inducible in
inflammatory, cardiovascular and neurological diseases (Bader et al.,
2000; Leeb-Lundberg et al., 2005; Rodi et al., 2005). The preferential
endogenousagonists of B1R are the kininase Imetabolites des-Arg9-BK
and des-Arg10-KD (Marceau, 1995; Marceau et al., 1997).
Recent findings suggest that the kallikrein-kinin system could
also contribute to the development of diabetic retinopathy (Phipps
and Feener, 2008; Wilkinson-Berka and Fletcher, 2004). Diabetic
retinopathy is characterized by progressive alterations of the retinal
microvasculature leading to breakdown of the blood-retinal barrier,
angiogenesis, retinal detachment and vision loss. Hyperglycemia
initiates a series of pathological events in the retinal vessels
including pericyte and endothelial cells loss, basement membrane
thickening, microaneurysms and vascular leakage. Retinal hae-
morrhages and capillary occlusion induce the formation of areas of
vascular non-perfusion which trigger the proliferation of new
blood vessels (Frank, 2004). Endothelial cell dysfunction and retinal
blood flow alterations also contribute to the development of dia-
betic retinopathy. Alterations of retinal blood flow are known to
appear early in the progression of diabetic retinopathy in patients
(Bursell et al., 1996; Clermont and Bursell, 2007; Grunwald et al.,
1996; Kawagishi et al., 1995) and in animal models of diabetes
(Alder et al., 1998; Clermont and Bursell, 2007; Cringle et al., 1993;
Higashi et al., 1998; Sutera et al., 1992). Components of the kalli-
krein-kinin system are known to be expressed in the human, rabbit
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and rat retina (Kuznetsova et al., 1991; Lim et al., 2008; Ma et al.,
1996; Takeda et al., 1999). Particularly, B1R is overexpressed in
the retina of Streptozotocin (STZ)-induced diabetic rats as early as
4 days after diabetes induction through a mechanism involving
oxidative stress (Abdouh et al., 2003, 2008). In STZ-diabetic rats,
B1R mediates vasodilation of retinal microvessels in vitro (Abdouh
et al., 2003) and contributes to the breakdown of blood-retinal
barrier in vivo (Abdouh et al., 2008; Lawson et al., 2005). These
results suggest a role for B1R in the development of vascular
alterations in the diabetic retina.
Therefore, the objective of the present study was to determine
whether B1R is involved in retinal blood flow changes in the early
stages of diabetes in the model of STZ-treated rat. The presence of
B1R in the retina of 4-day and 6-week STZ-diabetic rats was
assessed by Western blot analysis. The ability of the B1R antagonist
SSR240612 (Gougat et al., 2004) to prevent retinal perfusion
abnormality was measured by quantitative autoradiography. The
impact of the antagonist was compared to cortical blood flow
changes in the same animals.
2. Material and methods
2.1. STZ-diabetic rats
All experimental methods and animal care procedures were
approved by the local institutional animal care committee at the
University of Montreal, in accordance to the Canadian Council on
Animal Care. Male Wistar rats (n¼ 77) weighting 200e250 g were
purchased from Charles River (St-Constant, QC, Canada) and
housed two per cage in a room under controlled temperature
(23 C), humidity (50%) and lighting (12-hour light/dark cycle) with
food and water provided ad libitum. For the induction of diabetes,
rats received a single i.p. injection of Streptozotocin (STZ, 65 mg/kg,
Sigma-Aldrich, Oakville, ON, Canada). Age-matched controls were
injected with vehicle (sterile saline 0.9%, pH. 7.4). Glucose
concentrations were measured in blood samples obtained from
the tail vein with a commercial blood glucose analyzer (Accusoft;
Roche Diagnostics, Laval, QC, Canada) 48 h following STZ injection.
Only STZ-treated rats with blood glucose concentration higher
than 20 mmol/L were considered as diabetic. Rats showing
a normal glycemia after STZ injectionwere discarded. Glycemiawas
measured once a week and just before experimentation to confirm
that STZ-treated rats were diabetic.
2.2. Measurement of B1R expression in the retina of control
and diabetic rats by Western blot analysis
An anti-B1R antibody was raised in rabbits (Biotechnology
Research Institute, Montreal, QC, Canada; http://www.irb.cnrc.gc.ca)
against a conserved amino acid sequence from the B1R protein of
mouse and rat aligned using ClustalW software (http://www.ebi.ac.
uk/Tools/clustalw2). The used epitope contained 15 amino acids
(VFAGRLLKTRVLGTL) localized in the C-terminal part of the B1R
protein. Care was taken to avoid sequence regions containing
significant similarities to related mammalian proteins, including
B2R. Two negative controls were run: first, the pre-immune serum
was tested and second, B1R antibodies were pre-absorbed with the
peptide which served for immunization. The specificity of B1R
antibodies was further determined in knock-out mice tissues and
the results showed the absence of B1R protein in knock-out mouse
and very low expression in wild type mouse (Lin et al., 2010).
Control (n¼ 8) and diabetic (n¼ 8) rats were anaesthetised with
pentobarbital (60 mg/kg, i.p.). The eyes were dissected out, the
retinae were isolated, immediately frozen in isopentane (55 C)
and stored at 80 C. The presence of B1R in other ocular tissues
was not assessed. Retinae were homogenised in Phosphate Buffer
Saline (PBS) containing a cocktail of proteases inhibitors (Sigma-
Aldrich, Canada). The homogenates were then centrifuged at 500 g
for 5 min. Supernatants were recovered and protein concentration
was determined by the BCA method (Thermo Scientific, USA), and
Bovine Serum Albumin (BSA) was used as standard protein. Ten mg
of total proteins were loaded in each well of 10% SDS-PAGE. The
samples were electrophoresed and transferred onto nitrocellulose
membranes. The efficiency of the overall procedure was monitored
by Ponceau red staining. The membranes were blocked with
a commercial blocking buffer from Thermo in PBS-T (Phosphate
Buffer Saline -Tween 20, 0.1%), probed with the specific antibody at
1/1000 dilution followed by probing with an HRP (Horseradish
Peroxidase)-linked goat anti-rabbit secondary antibody (Santa Cruz
Biotech, CA, USA) at 1/25,000 dilution. All incubations with anti-
bodies were performed in the commercial blocking buffer.
Membranes were rinsed adequately between every stepwith PBS-T
and revealed using Enhanced Chemiluminescence Detection
System (ECL) (Super-Signal, Thermo Scientific, Canada). Dynein
was used as standard protein and revealed with mouse anti-dynein
monoclonal antibody (Santa Cruz Biotech, CA, USA) at a 1:25,000
dilution. HRP-linked goat anti-mouse (Santa Cruz Biotech, CA, USA)
was used as secondary antibody at a 1:25,000 dilution. A quanti-
tative analysis of the protein was performed by densitometry using
anMCID image analysis system (Imaging Research, St. Catharines,
ON, Canada).
2.3. Measurement of retinal and cerebral blood flow in diabetic rats
by quantitative autoradiography
Changes of retinal and cerebral blood flow were measured
at 4 days and 6weeks after the induction of diabetes by quantitative
autoradiography using the diffusible radioactive tracer N-isopro-
pyl-p-14C-iodoamphetamine ([14C]-IMP) as previously described
(Deschenes et al., 2010; Pouliot et al., 2009; Vaucher et al., 1997).
Polyurethane catheters were inserted into the femoral vein (Micro-
Renathane, I.D. 0.04000, O.D. 0.02000, Braintree Scientific, Braintree,
MA, USA) and artery (Tygon Micro Bore, I.D. 0.01000, O.D. 0.03000,
Small Parts, Miramar, FL, USA) under 1.5% isoflurane (induction of
anesthesia with 3% isoflurane for 5 min). During this procedure,
body temperature was monitored with a rectal thermometer and
maintained at 37 C by a heating pad (FHC, Bowdoinham, ME).
Before and immediately after the surgery, the topical anesthetic
lidocaine hydrochloride 2% (AstraZeneca, Mississauga, ON, Canada)
was applied on the skin incision to minimize pain. Rats were then
installed in a hammock and left under minimal restraint over a 2-h
period to recover from anesthesia. Body temperature was main-
tained at 37 C with a heating lamp and both blood pressure and
heart rate were monitored from the tail using a non-invasive blood
pressure cuff system (BP1000, Kent Scientific Corporation, Tor-
rington, CT, USA) until the measurement of the retinal and cerebral
blood flow. Blood chemistry was measured with a veterinarian
clinical blood gases and electrolytes analyzer (i-STAT, HESKA, Fort
Collins, CO), from arterial blood samples collected via the arterial
catheter.
Forbothdurationofdiabetes, ratsweredivided in4groups: control,
control treated with the B1R antagonist SSR240612, STZ-diabetic and




Aventis R&D,Montpellier, France) is a highly selective ligand for B1R
(Gougat et al., 2004). It was given by gavage (10 mg/kg) 3 h before
the autoradiography. The dose of 10 mg/kg was found effective to
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block B1R-mediated effects in several paradigms in vivo (Gougat
et al., 2004; Dias et al., 2007, 2010). SSR240612 was dissolved in
a solution of dimethylsulphoxide (0.5%), ethanol (5%) and Tween-80
(5%) and the solution was completed with distilled water (vehicle)
and administered in a volume of 1 ml by 100 g of body weight to
control and STZ-diabetic rats. Untreated control and STZ-diabetic
rats received the vehicle by gavage.
[14C]-IMP ((D,L)-N-Isopropyl-4- [14C]-iodo(phenyl)amphetamine,
100 mCi/kg; PerkinElmer, Boston, MA, USA, custom synthesis) was
dissolved in 600 ml of saline (injectable 0.9% NaCl solution) and
infused in fully conscious rats over a 30 s period at a constant rate of
1.2 ml/min using an infusion pump (PHD 2000, Harvard Apparatus,
Holliston, MA, USA) through the femoral vein. An average of 20e24
arterial blood samples (10 ml) were collected continuously from the
beginning of [14C]-IMP injection to the sacrifice of the animal (2 min)
in order to evaluate the arterial contamination curve. Blood samples
were digested in 300 ml of soluene (PerkinElmer, Boston, MA, USA)
for 2 h at 37 C. A total of 5 ml of scintillation fluid (Ultimagold,
Perkin Elmer, Boston,MA,USA)was then added and the radioactivity
was counted in a scintillation counter (LS6500, Beckman Coulter,
Mississauga, ON, Canada). The rats were sacrificed by decapitation
2 min after the beginning of the infusion. The eyes and brain were
quickly removed within 3 min. A small incision on the superior
eyelid was made to indicate the orientation of the eyes and the eyes
together with the attached superior eyelid were then harvested. The
eyes were immediately excised, the lens removed and the eye cup
immersed in a solution of 4% paraformaldehyde for post-fixation.
After a one h fixation, retinae were removed from the eye cup, and
dissected into four quadrants (superior, inferior, nasal and temporal).
The vitreous bodywas carefully removed from the retinae using fine
paint brush. Retinae were whole-mounted on a glass slide with the
ganglion cells layer away from the slide. A small incision was made
on the retina to indicate the nasal quadrant. Thewhole-mount retina
was then exposed to anX-rayfilm (Hyperfilm,GEHealthcare Ltd, UK)
for 4 days togetherwith a set of [14C]-standards (ARC, St. Louis, USA).
The autoradiograms were analyzed using the computerized image
analysis MCID Basic Software (v7.0, Interfocus Imaging, Linton, UK).
For the CBF quantification at 4 days of diabetes, the brainwas frozen
in isopentane (55 C) and subsequently sliced in 20 mm thick
coronal sections using a cryostat (22 C) for autoradiography. Slices
were exposed on X-ray film for 8 days with [14C]-standards (Amer-
shamBiosciences, UK). For experiment at 6weeks of diabetes, a piece
of the frontal cerebral cortexwasdissected,weighted anddigested in
soluene overnight at 37 C for liquid scintillation counting. Previous
study showed that the values measured by the two methods of
sampling are equivalent (Pouliot et al., 2009).
2.4. Calculation of retinal and cerebral blood flow
Retinal and cerebral blood flow was evaluated using the prin-
ciple of indicator-fractionation technique (Greenberg et al., 1999;
Lear et al., 1982; Pouliot et al., 2009) using the equations Eq. (1)
for digested cortex and autoradiographic analysis of CBF per-
formed with 20 mm thick sections and Eq. (2) for autoradiographic

















where F is the blood flow (ml/100 g/min), CIMP (T) is the radioac-
tivity measured on the autoradiogram or digested tissue (mCi/g) at
the time T (min) of sacrifice and Ca(t) is the arterial concentration of
radioactivity measured in the blood samples (mCi/ml). For autora-
diographic measurements in the retina, CIMP(T) was read from
circular regions of interest of 0.8 mm2 (1 mm diameter) distributed
at the 1, 2 and 3 mm isopters away from the center of the optic
nerve head in all retinal quadrants (Pouliot et al., 2009). Since the
common radioactive standards used for autoradiography are
calibrated for 20 mm thick sections and the rat retina thickness
is 20511 mm (Duong et al., 2008), the measured [14C]-IMP
concentration values from autoradiograms (CIMP(T)) were uniformly
corrected by a factor 10 (Pouliot et al., 2009). For the brain, 8 regions
of interest (area adjusted to the region size, 2e9 mm2) related to
vision or in control areas were selected and analyzed at 3 coronal
levels from Bregma: APþ 1.6 mm; cingulate, frontal cortex, stria-
tum; AP 4.5 mm; parietal cortex, hippocampus, dorsolateral
geniculate nucleus (DLG); AP 6.3 mm; occipital cortex, superior
colliculus.
2.5. Statistical analysis
Student’s t-test on unpaired samples was used for comparison of
B1R expression in the retina of control and STZ-diabetic rats. One-
way ANOVA and Bonferroni post-hoc tests were performed for
comparison between control group, control group treated with
SSR240612, diabetic group and diabetic group treated with
SSR240612 for each duration of diabetes separately (4 days and
Table 1
Effect of diabetes and B1R antagonist SSR240612 on the physiological parameters monitored in the conscious rats after two hours of recovery from anaesthesia and prior to the
injection of [14C]-IMP.
4 days 6 weeks
CTL (n¼ 12) CTLþ SSR (n¼ 6) STZ (n¼ 8) STZþ SSR (n¼ 8) CTL (n¼ 7) CTLþ SSR (n¼ 6) STZ (n¼ 7) STZþ SSR (n¼ 7)
Body weight (g) 257 17 260 29 239 26 255 17 419 31 472 28 319 71* 314 65**
Glycemia (mmol/L) 6 1 7 1 26 5*** 29 5*** 7 2 7 2 31 4*** 31 5***
Body temperature (C) 37.5 0.3 37.8 0.3 37.2 0.3 37.4 0.3 37.9 0.4 37.7 0.4 37.5 0.3 37.7 0.3
Mean blood pressure (mmHg) 116 13 120 5 126 10 126 11 119 15 117 10 122 9 127 12
Heart Rate (Beats/min) 503 52 475 33 459 56 497 35 419 52 528 134 469 130 473 84
Arterial pH 7.45 0.01 7.45 0.02 7.45 0.03 7.45 0.02 7.47 0.02 7.45 0.01 7.42 0.05 7.45 0.04
Arterial pO2 (mmHg) 86 4 85 3 85 5 82 2 86 4 85 6 87 6 87 4
Arterial pCO2 (mmHg) 38 2 38 3 38 1 39 2 39 1 40 2 33 5** 39 2
Arterial HCO3 (mmol/L) 26 1 26 1 26 2 27 1 28 2 27 1 21 4** 27 3
Hematocrit (% PCV) 40 4 39 2 41 2 42 1 44 2 45 3 50 6* 48 2
Values are means SD. The selective B1R antagonist SSR240612 was administered in the CTLþ SSR and STZþ SSR groups. The vehicle only was administered in CTL and STZ
groups. pO2, pCO2, partial gas pressure of oxygen and carbon dioxide, respectively; HCO3, bicarbonate; CTL, control group; PCV, packed cell volume STZ, diabetic group; SSR,
SSR240612. * p< 0.05, ** p< 0.01, *** p< 0.001 compared with control group.
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6 weeks of diabetes) for (1) the physiological parameters, (2) the
regional RBF in each isopter, (3) the CBF. A significance level of
p< 0.05 was chosen.
3. Results
3.1. Physiological parameters
Glycemia was significantly increased in 4-day and 6-week dia-
betic rats compared to age-matched control rats (p< 0.001,
Table 1). Treatment with SSR240612 had no effect on glycemia in
both control and STZ-diabetic rats at both end points. All other
physiological parameters were not changed in 4-day diabetic group
treated or notwith SSR240612 compared to the control group. Body
temperature, blood pressure, heart rate, pH and pO2 were not
affected in 6-week diabetic rats treated or not with SSR240612
(p> 0.05, Table 1). However, body weight was significantly
decreased in 6-week diabetic rats treated or not with SSR240612
compared to age-matched controls (p< 0.01, Table 1), which is
commonly found in diabetic animals. pCO2 and HCO3 were
significantly decreased (p< 0.01) and hematocrit was significantly
increased (p¼ 0.02), in 6-week diabetic rats not treated with
SSR240612 compared to age-matched controls, which might indi-
cate a slight acid-base unbalance which is often seen in diabetic
animals. This dysregulation of acid-base balance was not seen in
SSR240612 treated animals (p> 0.05, Table 1), which needs further
clarification.
3.2. Expression of B1R in the retina of diabetic rats
The level of B1R protein measured by Western blotting was
significantly increased in the retina of 4-day (326%, p¼ 0.000) and
6-week (237%, p¼ 0.001) diabetic rats compared to age-matched
controls (Fig. 1).
3.3. Effect of B1R antagonist SSR240612 on retinal blood flow
measured by quantitative and regional autoradiography
RBF was not affected by hyperglycemia in 4-day diabetic rats
compared to age-matched control rats for all the retina subregions
measured (p> 0.05, Table 2, Figs. 2 and 3). B1R antagonist
SSR240612 treatment had no effect on RBF in control animals
(p> 0.05, Table 2, Figs. 2 and 3)e the slight non significant decrease
of RBF may be attributed to a low level of B1R expression in control
animals e but significantly decreased RBF in 4-day diabetic rats
compared to control rats at 2 mm isopter (21%, p¼ 0.026) and
3 mm isopter (26%, p¼ 0.005, Table 2, Figs. 2 and 3).
In contrast, RBF was significantly decreased in 6-week diabetic
rats compared to control rats at 1 mm isopter (29%, p¼ 0.003),
2 mm isopter (29%, p¼ 0.006) and 3 mm isopter (39%, p¼ 0.001). In







































Fig. 1. Protein expression of B1R in the retina of diabetic rats measured by Western blot. B1R was upregulated in the retina at 4 days (A) and 6 weeks (B) after the induction of
diabetes. ***p< 0.001, significantly different from control group.
Table 2
Effect of diabetes and B1R antagonist SSR240612 on retinal and cerebral blood flow.
4 days 6 weeks
CTL CTLþ SSR STZ STZþ SSR CTL CTLþ SSR STZ STZþ SSR
Retinal blood flow (n¼ 12) (n¼ 6) (n¼ 8) (n¼ 8) (n¼ 7) (n¼ 6) (n¼ 7) (n¼ 7)
Optic nerve 111 18 102 13 98 25 86 18 102 19 90 17 72 29 81 9
1 mm isopter 119 18 114 10 113 25 97 22 118 13 102 9 84 25* 90 7*
2 mm isopter 108 15 106 5 100 18 85 19* 108 12 92 9 77 26* 83 6*
3 mm isopter 87 15 98 4 80 16 64 13* 99 13 82 8 62 25* 71 7*
Cerebral blood flow (n¼ 6) (n¼ 6) (n¼ 5) (n¼ 5) (n¼ 7) (n¼ 6) (n¼ 7) (n¼ 7)
Frontal cortex 127 12 105 11 121 15 105 32 116 26 87 10 79 24* 81 18*
Values are means SD and are expressed in ml/100 g/min. The selective B1R antagonist SSR240612 was administered in the CTLþ SSR and STZþ SSR groups. The vehicle only
was administered in CTL and STZ groups. CTL, control group; STZ, diabetic group; SSR, SSR240612. * p< 0.05 compared with control group.
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not statistically significant (p¼ 0.171). B1R antagonist SSR240612
treatment significantly decreased RBF in 6-week diabetic rats
compared to age-matched control rats at 1 mm isopter (24%,
p¼ 0.016), 2 mm isopter (24%, p¼ 0.034) and 3 mm isopter (29%,
p¼ 0.012). However, this decrease was not significant compared to
6-week diabetic rats not treated with SSR240612 (Table 2, Fig. 3).
3.4. Effect of B1R antagonist SSR240612 on cerebral blood flow
Blood flow in frontal cortex was not altered in 4-day diabetic
rats compared to controls and not changed by the B1R antagonist
treatment (p> 0.05, Table 2, Fig. 4). However, it was significantly
reduced (32%) in comparison to age-matched controls in 6-week
diabetic rats treated (p¼ 0.012, Table 2, Fig. 4) or not (p¼ 0.014,
Table 2, Fig. 4) with SSR240612, as shown in the retina of diabetic
rats. Treatment with SSR240612 had no effect on CBF in 6-week
control rats (p> 0.05). There was no regional variation since cere-
bral blood flow measured by autoradiography in cingulated cortex,
striatum, parietal cortex, hippocampus, DLG, occipital cortex, and
superior colliculus was not altered by diabetes and B1R antagonist
treatment (data not shown).
4. Discussion
The results clearly show that kinin B1R is upregulated in the STZ-
rat retina up to 6 weeks following diabetes induction. The B1R
Fig. 2. Representative whole-mount retina autoradiograms displayed in pseudocolor from a control rat treated with vehicle, a control rat treated with the selective B1R antagonist
SSR240612, a STZ-diabetic rat treated with vehicle and a STZ-diabetic rat treated with SSR240612 at 4 days (A) and 6 weeks (B) after diabetes induction. The correspondence
between pseudocolor and blood flow values (ml/100 g/min) is represented on the scale on the right side of the figure.
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Fig. 3. Effect of the treatment with the selective B1R antagonist SSR240612 on retinal blood flow. Percent change (versus control) of retinal blood flow were measured in diabetic
rats treated with the selective B1R antagonist SSR240612 (STZþ SSR) or vehicle (STZ) at 4 days (A) and 6 weeks (B) after diabetes induction and compared with aged matched sham
animals (CTL and CTLþ SSR). Regional blood flow was measured on each isopter by autoradiography. *p< 0.05, significantly different from control group.
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blockade reduced the RBF at 4 days but not at 6weeks. These results
suggest that the B1R is tonically activated by endogenous kinins and
contributes to prevent diabetes-induced reduction of retinal blood
flow 4 days following STZ injection. This positive effect of kinins on
retinal blood flow was not maintained 6 weeks following STZ
injection.
4.1. Retinal blood flow in diabetic rats
Our results demonstrated that retinal blood flowwas not altered
in 4-day diabetic rats but was significantly decreased in 6-week
diabetic rats compared with age-matched controls. This is the first
study evaluating RBF in the early days of diabetes onset. Previous
studies using fluorescein angiography reported decreased RBF in
STZ-diabetic rats at one (Bursell et al., 1992; Clermont et al., 1994;
Takagi et al., 1996), 2 and 4 weeks (Higashi et al., 1998) of dia-
betes, although some studies using microsphere technique or
hydrogen clearance reported increased RBF in STZ-diabetic rats
from 3 to 6 weeks after diabetes induction (Cringle et al., 1993;
Pugliese et al., 1990; Sutera et al., 1992; Tilton et al., 1989). Our
findings suggest a reduction of blood flow in the diabetic rat retina.
Moreover, our results show that the deficit of blood flow is not
a primary event since it is not present at the fourth day of diabetes
induction. In diabetic patients, previous studies on retinal blood
flow have also provided diverse results. Decreased retinal blood
flow in diabetic patients with absent or mild diabetic retinopathy
was reported (Bursell et al., 1996; Feke et al., 1994; Feng et al., 2000)
as well as a tendency to increased blood flow as retinopathy
progresses (Clermont et al., 1997). Other studies also reported
increased blood flow in diabetic patients with no or mild diabetic
retinopathy (Grunwald et al., 1996; Pemp et al., 2010). However,
most of the studies agree that impairment of retinal blood flow
occurs in the early steps of diabetic retinopathy progression and
even prior to the development of clinical signs of the disease.
4.2. Effect of the selective B1R antagonist SSR240612 on retinal
blood flow
The principal series of results show that the B1R in the retina of
STZ-diabetic rat could be involved in blood flow regulation during
diabetes in the presence of appropriate endogenous ligands.
Accordingly, B1R appeared to maintain the blood flow in the dia-
betic retina at 4 days but not at 6 weeks. The B1R protein expression
within the retina early on after diabetes induction (4 days)
corroborates previous findings on B1R binding sites (Abdouh et al.,
2003), but its presence at 6 weeks after diabetes onset is shown
here for the first time. B1R being indicative of inflammatory or
oxidative processes, this data suggests that the retina undergoes
a stress from the beginning of the hyperglycemia, which persists as
long as hyperglycemia was maintained. The cumulative effect of
this process would most likely damage the retina. Previous in vitro
study showed selective and dose-dependent vasodilation of retinal
vessels in isolated retina of STZ-diabetic rats in the presence
of selective B1R agonists; a response that involved intracellular
calcium mobilization, release of nitric oxide and prostaglandins in
endothelial cells (Abdouh et al., 2003). Thus, the B1R seems to have
a direct action on blood vessel endothelium. The effect of B1R is
most likely directly related to hyperglycemia caused by STZ since it
has already been shown that retinal vessels from 4-day STZ-rats
that failed to develop hyperglycemia do not dilate in response to
B1R agonist (Abdouh et al., 2003). As RBF was slightly but not
significantly decreased in 4-day diabetic rats without SSR240612
treatment but was strongly decreased with SSR240612 treatment,
this suggests that endogenous kinins may act on B1R to induce
vasodilation and maintain a normal blood flow in the diabetic
retina. This suggests a protective role for B1R on the retinal circu-
lation at the very early stage of diabetes.
The positive effect of B1R on retinal perfusion that was present
in 4-day diabetic rats was not preserved 6 weeks following dia-
betes induction since B1R blockade did not alter the blood flow
level compared to diabetic rats without SSR240612 treatment. The
decrease of blood flow in diabetic animals as well as the absence
of a physiological response to the B1R antagonist is indicative of
either an absence of endogenous kinins that could activate B1R or
the presence of other vasoactive substances that could contribute
to regulation of blood flow. The unbalance between vasocon-
strictors and vasodilators in the diabetic retina is a major cause of
RBF alteration. Vasoactive molecules such as Endothelin-1 (ET-1)
and Angiotensin-II (Ang-II) are known to be expressed in the
retina and contribute to retinal vasoconstriction and reduction of
RBF in diabetic rats (Bursell et al., 1995; Horio et al., 2004). The
modulation of RBF by vasoconstrictive molecules could therefore
partially mask the vasodilatory effect of B1R at 6 weeks of diabetes.
On the other hand, the vasodilatory effect of B1R could be altered
because of an endothelial dysfunction and decreased NO-mediated
response in 6-week diabetic rats, since B1R is known to cause
vasodilation of retinal vessels via an endothelium-dependent
mechanism (Abdouh et al., 2003). In the retina and many vascular
beds, endothelium-dependent vasodilation was found to be
diminished in diabetes (De Vriese et al., 2000; Edgley et al., 2008;
Oyama et al., 1986; Schmetterer et al., 1997; Tabit et al., 2010;
Taylor et al., 1992).
4.3. Effect of the selective B1R antagonist SSR240612 on cerebral
blood flow in diabetic rats
Our results show that blood flow in frontal cortex was not
altered 4 days after diabetes induction but was strongly reduced at
6 weeks. Previous studies have also reported decreased blood
flow in cortex in diabetic rats 2 to 5 weeks post-STZ injection using
n- [14C]butanol (Harik and LaManna, 1988) and [14C]-iodoantipyr-
ine (Duckrow et al., 1987). A reduction of blood flow was also
reported at 16 and 20weeks following diabetes induction (Knudsen
et al., 1991; Manschot et al., 2003). However, some studies reported
normal (Granstam and Granstam, 2003) and increased blood flow
(Sutera et al., 1992) in the brain of STZ-diabetic rats. In diabetic rats,
changes of blood flow in frontal cortex were similar to changes of





























Fig. 4. Effect of the treatment with the selective B1R antagonist SSR240612 on cerebral
blood flow. Percent change (versus control) of cerebral blood flow was measured in
control and diabetic rats treated with B1R antagonist SSR240612 compared with CTL
and STZ groups treated with vehicle only. The blood flow was measured in frontal
cortex 4 days and 6 weeks after diabetes induction. *p< 0.05, significantly different
from control group.
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significantly decreased at 6weeks in both organs. This suggests that
the diabetes has a tendency to induce a general deficit in blood flow
to the same extent in the retina and frontal cortex. However, B1R
antagonist in 4-day diabetic rats induced a strong decrease of blood
flow in the retina, whereas it had no effect on blood flow in frontal
cortex. These results suggest that B1R, which is overexpressed in
the cortex of diabetic rats as early as 4 days after diabetes induction
(Campos et al., 2005) does not exert the same protective effect on
cortical blood flow as seen in the retina. This may reflect the lower
level of endogenous kinins or B1R in the brain compared to retina.
This could be related to the stronger reactivity of the retina to
oxidative stress compared to the brain (Grammas and Riden, 2003).
5. Conclusion
In summary, our results demonstrated that B1R is overexpressed
in the diabetic rat retina and exerts a protective effect to reduce RBF
deficit in 4-day diabetic rats but is not involved in the RBF reduction
present at 6 weeks of diabetes. Its involvement in other aspects of
diabetic retina damage deserves further investigation.
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